TUDRIQEV Approval in Advanced Melanoma: Mechanism, Clinical Evidence

σε πρόσθεσε στο Health

2026-09-06 19:55:33 -

Replimune has reached an important regulatory milestone in oncology following the accelerated FDA approval of tudriqev (vusolimogene oderparepvec-wtpg), previously referred to as RP1. The therapy is approved in combination with Bristol Myers Squibb's OPDIVO (nivolumab) for adults with unresectable or advanced cutaneous melanoma that has progressed after treatment with an anti-PD-1 therapy. The...

0 Σχόλια 0 Μοιράστηκε 4 Views 0 Προεπισκόπηση